tetano
Editor, Senior Moderator
Front Immunol
. 2024 Jul 26:15:1416375.
doi: 10.3389/fimmu.2024.1416375. eCollection 2024. Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2
Juan Liu[SUP] 1 [/SUP], Huafeng Han[SUP] 1 [/SUP], Binbin Yang[SUP] 1 [/SUP], Naifang Zhang[SUP] 1 [/SUP], Jing Li[SUP] 1 [/SUP], Xicheng Chen[SUP] 1 [/SUP], Jie Wu[SUP] 1 [/SUP], Yingying Zhao[SUP] 1 [/SUP], Yongsheng Yang[SUP] 1 [/SUP]
Affiliations
With the rapid global spread of COVID-19 and the continuous emergence of variants, there is an urgent need to develop safe and effective vaccines. Here, we developed a novel mRNA vaccine, HC009, based on new formulation by the QTsome delivery platform. Immunogenicity results showed that the prime-boost immunization strategy with HC009 was able to induce robust and durable humoral immunity, as well as Th1-biased cellular responses in rodents or non-human primates (NHPs). After further challenge with live SARS-CoV-2 virus, HC009 provided adequate protection against virus infection in hACE2 transgenic mice. Therefore, HC009 could provide significant immune protection against SARS-CoV-2.
Keywords: SARS-CoV-2; humoral immunity; immune protection; immunogenicity; mRNA vaccine; prime-boost.
. 2024 Jul 26:15:1416375.
doi: 10.3389/fimmu.2024.1416375. eCollection 2024. Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2
Juan Liu[SUP] 1 [/SUP], Huafeng Han[SUP] 1 [/SUP], Binbin Yang[SUP] 1 [/SUP], Naifang Zhang[SUP] 1 [/SUP], Jing Li[SUP] 1 [/SUP], Xicheng Chen[SUP] 1 [/SUP], Jie Wu[SUP] 1 [/SUP], Yingying Zhao[SUP] 1 [/SUP], Yongsheng Yang[SUP] 1 [/SUP]
Affiliations
- PMID: 39131158
- PMCID: PMC11310568
- DOI: 10.3389/fimmu.2024.1416375
With the rapid global spread of COVID-19 and the continuous emergence of variants, there is an urgent need to develop safe and effective vaccines. Here, we developed a novel mRNA vaccine, HC009, based on new formulation by the QTsome delivery platform. Immunogenicity results showed that the prime-boost immunization strategy with HC009 was able to induce robust and durable humoral immunity, as well as Th1-biased cellular responses in rodents or non-human primates (NHPs). After further challenge with live SARS-CoV-2 virus, HC009 provided adequate protection against virus infection in hACE2 transgenic mice. Therefore, HC009 could provide significant immune protection against SARS-CoV-2.
Keywords: SARS-CoV-2; humoral immunity; immune protection; immunogenicity; mRNA vaccine; prime-boost.